Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBITDA Multiple | 15.6x - 17.3x | 16.4x |
| Selected Fwd EBITDA Multiple | 10.6x - 11.8x | 11.2x |
| Fair Value | ₩7,976 - ₩10,475 | ₩9,225 |
| Upside | -28.1% - -5.6% | -16.9% |
| Benchmarks | Ticker | Full Ticker |
| Aprogen Biologics Inc. | A003060 | KOSE:A003060 |
| Ildong Pharmaceutical Co., Ltd. | A249420 | KOSE:A249420 |
| KOREA PHARMA Co., Ltd. | A032300 | KOSDAQ:A032300 |
| CMG Pharmaceutical Co., Ltd. | A058820 | KOSDAQ:A058820 |
| Kyongbo Pharmaceutical Co., Ltd | A214390 | KOSE:A214390 |
| HANDOK Inc. | A002390 | KOSE:A002390 |
| - | - | - |
| Select LTM EBITDA Multiple | |||||||
| Benchmark Companies | |||||||
| A003060 | A249420 | A032300 | A058820 | A214390 | A002390 | ||
| KOSE:A003060 | KOSE:A249420 | KOSDAQ:A032300 | KOSDAQ:A058820 | KOSE:A214390 | KOSE:A002390 | ||
| Historical EBITDA Growth | |||||||
| 5Y CAGR | NM- | 7.2% | 0.1% | -1.5% | 4.0% | -15.7% | |
| 3Y CAGR | NM- | NM- | 6.3% | NM- | 55.1% | -24.9% | |
| Latest Twelve Months | 19.9% | 248.9% | 2.7% | -22.0% | 32.6% | -40.3% | |
| Historical EBITDA Profit Margin | |||||||
| 5 Year Average Margin | -19.2% | -1.3% | 10.1% | 5.6% | 7.4% | 8.5% | |
| Prior Fiscal Year | -56.4% | -4.2% | 10.4% | 6.0% | 8.0% | 6.7% | |
| Latest Fiscal Year | -58.6% | 6.1% | 10.9% | 4.4% | 9.6% | 4.1% | |
| Latest Twelve Months | -58.6% | 6.1% | 10.9% | 4.4% | 9.6% | 4.1% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 3.55x | 0.67x | 1.63x | 2.46x | 0.85x | 0.73x | |
| EV / LTM EBITDA | -6.1x | 11.1x | 14.9x | 55.9x | 8.9x | 17.7x | |
| EV / LTM EBIT | -4.1x | 36.1x | 21.8x | 239.3x | 19.4x | -142.0x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBITDA | -6.1x | 11.1x | 55.9x | ||||
| Historical EV / LTM EBITDA | 6.7x | 7.6x | 17.7x | ||||
| Selected EV / LTM EBITDA | 15.6x | 16.4x | 17.3x | ||||
| (x) LTM EBITDA | 20,937 | 20,937 | 20,937 | ||||
| (=) Implied Enterprise Value | 326,790 | 343,989 | 361,189 | ||||
| (-) Non-shareholder Claims * | (216,897) | (216,897) | (216,897) | ||||
| (=) Equity Value | 109,892 | 127,092 | 144,291 | ||||
| (/) Shares Outstanding | 13.8 | 13.8 | 13.8 | ||||
| Implied Value Range | 7,984.32 | 9,233.96 | 10,483.60 | ||||
| FX Rate: KRW/KRW | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 7,984.32 | 9,233.96 | 10,483.60 | 11,100.00 | |||
| Upside / (Downside) | -28.1% | -16.8% | -5.6% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | A003060 | A249420 | A032300 | A058820 | A214390 | A002390 | |
| Enterprise Value | 239,421 | 413,081 | 132,501 | 244,215 | 202,803 | 369,673 | |
| (+) Cash & Short Term Investments | 38,319 | 84,872 | 37,695 | 76,794 | 6,128 | 56,044 | |
| (+) Investments & Other | 91,994 | 23,729 | 5,836 | 46,463 | 11,121 | 102,250 | |
| (-) Debt | (154,017) | (205,548) | (22,902) | (79,965) | (91,433) | (373,394) | |
| (-) Other Liabilities | (199) | 1,701 | 0 | 0 | 0 | (1,798) | |
| (-) Preferred Stock | 0 | (7,228) | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 215,517 | 310,608 | 153,130 | 287,507 | 128,619 | 152,775 | |
| (/) Shares Outstanding | 311.0 | 27.9 | 10.9 | 138.9 | 23.9 | 13.8 | |
| Implied Stock Price | 693.00 | 11,120.00 | 14,040.00 | 2,070.00 | 5,380.00 | 11,100.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 693.00 | 11,120.00 | 14,040.00 | 2,070.00 | 5,380.00 | 11,100.00 | |
| Trading Currency | KRW | KRW | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |